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Effect of Macrophage Colony-Stimulating
Factor Receptor c-Fms Antibody
on Lipopolysaccharide-Induced Pathological
Osteoclastogenesis and Bone Resorption
Keisuke Kimura, Hideki Kitaura, Masahiko Ishida, Zaki Hakami,
Jafari Saeed, Haruki Sugisawa, and Teruko Takano-Yamamoto
Abstract Lipopolysaccharide (LPS) is a major component of Gram-negative bac-
teria cell walls and is a well-known potent inducer of inflammation and pathogens
of inflammatory bone loss. Formation of osteoclasts is highly dependent on the
presence of macrophage colony-stimulating factor (M-CSF) and receptor activator
of nuclear factor kappa-B ligand (RANKL). Recent reports indicate that biological
preparations, including anti-RANKL antibody and anti-tumor necrosis factor-α
antibody, positively influence rheumatoid arthritis and osteoporosis. In this study,
we aimed to investigate whether the M-CSF receptor c-Fms antibody would inhibit
the formation of osteoclasts. C57BL6/J mice were injected with either LPS, LPS
and anti-c-Fms antibody, anti-c-Fms antibody, or PBS into the supracalvariae.
Animals were sacrificed and calvariae fixation and demineralization were
performed. Histological sections of calvariae were stained for tartrate-resistant
acid phosphatase (TRAP). In mice administered with both LPS and the anti-c-
Fms antibody, osteoclast numbers were lower than those in mice administered with
LPS alone. Moreover, levels of TRACP-5b, a bone resorption marker in mice
serum, were lower in mice administered with both LPS and the anti-c-Fms antibody
than in mice administered with LPS alone. These results suggest that M-CSF and its
receptor are potential therapeutic targets in LPS-induced osteoclastogenesis, and
that the anti-c-Fms antibody might be useful for inhibition of inflammation-induced
bone erosion. In this study, we describe and discuss the effect the anti-c-Fms
antibody has on pathological osteoclastogenesis and bone resorption.
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22.1 Biological Effect of Macrophage Colony-Stimulating
Factor (M-CSF)
Macrophage colony-stimulating factor (M-CSF) is a known hematopoietic growth
factor and regulator of key functions of macrophages and monocytes. M-CSF
mediates the survival and proliferation of precursors of the monocyte and macro-
phage lineage and their differentiation into mature phagocytes [1, 2]. Macrophages,
in relation to the immune response, exist as phagocytes and antigen-presenting cells
[3, 4]. Furthermore, the activity of macrophages is associated with the regulation of
many biological processes and is dependent on the actual macrophage phenotype
induced under various inflammatory conditions [1]. Macrophages play an important
role in homeostasis, autoimmunization, and first defense during infection. Macro-
phages react to tissue damage through non-specific activation followed by
overproduction of proinflammatory factors within the pathological condition
[5]. Furthermore, allergen or self-antigen presentation on macrophages induces a
chronic inflammatory response and stultification of immunity. Primitive macro-
phages develop from hematopoietic cells and then differentiate into fetal macro-
phages. Monocytes are also differentiated from hematopoietic cells in the bone
marrow and fetal hematopoietic organs. Macrophages contribute as effectors of
metabolism and the host defense. When macrophages are depleted, bilirubin pro-
duction and host resistance to infection are severely reduced. Macrophage growth
factors induce macrophage differentiation and function. M-CSF-deficient mice are
deficient in monocytes, tissue macrophages, and osteoclasts and show osteopetrotic
phenotypes [6]. It has been reported that macrophages incorporate chemically
modified, low-density lipoprotein (LDL) and differentiate into foam cells in the
arterial wall [7]. When oxidized LDL binds to liver X receptor α, this upregulates
expression of its target genes and acts to remove cholesterol from macrophages.
Inflammatory signals downregulate the expression of liver X receptor α and
enhance lipid accumulation [7]. Therefore, macrophages play a pivotal role in
metabolism and host defense. Thus, the macrophage/monocyte growth factor,
M-CSF, plays an important role in these events.
22.2 The Role of M-CSF in Osteoclast Formation
and Bone Remodeling
Many cytokine contribute to osteoclast formation [8–12]. M-CSF is one of the
essential cytokine for osteoclastgenesis. M-CSF plays an important role in bone
remodeling and mediates osteoclast differentiation and the survival and prolifera-
tion of osteoclast precursors [13, 14]. The osteoclast, which is a unique bone
resorptive cell, is a member of the macrophage family. Osteoclastogenesis is
dependent on M-CSF and receptor activator of nuclear factor kappa-B ligand
(RANKL) [15]. Osteoclasts play a role in bone resorption and maintain bone
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homeostasis. This event was confirmed by the observation that osteopetrotic
(op/op) mutant mice, deficient in expression of M-CSF, show an osteopetrotic
phenotype [14]. Additionally, administration of soluble M-CSF to op/op mice
rescues their osteoclast formation potential and occurrence of osteoporosis
[6]. The functional relationship between M-CSF and its receptor is established in
mice lacking c-fms, which display the same phenotype as the op/op mouse. These
mice have decreased tissue macrophages and severe osteopetrosis owing to a lack
of osteoclasts [16–19]. Mice homozygous for the osteopetrosis mutation are char-
acterized by defective differentiation of osteoclasts, monocytes, and tissue macro-
phages, owing to the lack of M-CSF activity. It has been reported that the bone
marrow cavities were filled with spongious bone in young op/op mice. Conversely,
the bone marrow cavities were reconstructed and marrow hematopoiesis was
increased in old op/op mice [7]. Osteoclast and bone marrow macrophage cell
numbers were also increased in old op/op mice. However, many of the osteoclasts
were mononuclear not multinuclear cells and showed insufficiently developed
ruffled borders. Furthermore, in old op/op mice, lysosomes of bone marrow mac-
rophages were laden with abundant crystalloid materials, which was not observed
in young op/op mice. Although the number of Kupffer cells in the liver was not
increased in the old op/op mice, cell ultrastructural maturation was absent and some
crystalloid structures were observed [7]. M-CSF administration to old op/op mice
increased the number of Kupffer cells and induced lysosome formation in the
Kupffer cells. Furthermore, M-CSF administration reduced crystalloid structures
in the lysosomes of the Kupffer cells and permitted development of atypical ruffled
border in the osteoclasts [7]. These results suggest that the M-CSF-independent
mechanisms for macrophage and osteoclast development in old op/op mice are
restricted to the bone marrow. M-CSF plays important roles in the differentiation of
macrophages and osteoclasts and the production and function of lysosomes. Bind-
ing of M-CSF to c-Fms activates the receptor tyrosine kinase and induces auto-
phosphorylation of the dimer on selected tyrosine residues. The M-CSF/c-fms
signaling pathway leads to activated phosphorylation of Pl3K, cSrc, and ERK,
which are critical for proliferation and survival of osteoclast precursors [20, 21].
Rheumatoid arthritis (RA) is a highly complex condition, the pathogenesis of
which results from a host of cytokines produced by a variety of cells. While
RANKL and interleukin (IL)-1 are important participants in the development of
focal bone erosions, which eventuate in joint collapse, tumor necrosis factor (TNF)-
α is the principal and rate-limiting culprit, whose blockade dampens both the
inflammatory and osteoclastogenic components of the disease [22]. However,
blockade of TNF-α alone is insufficient to optimize arrest of inflammatory joint
disease, as coordinated treatment with IL-1 receptor antagonist (IL-1Ra) is more
effective [23]. Added to the potential complications attending TNF-α inhibition,
these observations underscore the importance of identifying new therapeutic can-
didates in this disease, a goal which can be achieved only by gaining insight into the
means by which TNF-α impacts target cells.
While M-CSF is constitutively produced by a range of mesenchymal cells, its
regulated secretion has pathological consequences in the context of the osteoclast.
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Thus, absence of estrogen, the cause of postmenopausal osteoporosis, is because of
enhanced bone resorption caused, at least in part, by increased production of
M-CSF by bone marrow stromal cells [24]. Similarly, the enhanced osteoclas-
togenesis observed following deletion of the β3 integrin gene is due to stimulated
M-CSF expression [25]. Regarding inflammatory osteolysis, the cytokine is
increased in the serum of patients with RA [26] and those with severe ankylosing
spondylitis [27], as well as in the synovial fluid around loose joint prostheses [28].
22.3 Biological Antibody Therapy for Bone Disease
Recently, biological preparations, including anti-RANKL antibody and anti-TNF-α
antibody, have been reported to positively influence RA, osteoporosis, and cancer
bone metastasis [29]. These antibodies act as decoys to prevent receptor binding
and therefore inhibit osteoclastogenesis. Denosumab, an anti-bone resorptive drug,
is a complete human-type monoclonal antibody for RANKL [30, 31]. Denosumab
has been shown to elicit an inhibitory effect on bone resorption in patients with
osteoporosis and RA. However, in patients with massive renal dysfunction,
denosumab administration increases the risk of hypocalcemia. Denosumab binds
to a specific loop structure on the RANKL molecule and inhibits its interaction with
its receptor, RANK [32]. When labeled with radioactivity, denosumab was detected
in the lymph nodes and spleen after subcutaneous administration, indicating posi-
tive RANKL binding of the drug within those tissues. Therefore, researchers and
clinicians are interested in the inhibitory effects of denosumab on bone resorption,
as well as its mode of action. Biological therapy by blocking the TNF-α receptor
is an efficacious RA treatment. TNF-α is produced primarily by activated macro-
phages and induces osteoclast formation via activated phosphorylation of P38,
JNK, and AP-1. This cytokine likely plays a key role in RA pathogenesis [11, 32,
33]. Infliximab is a chimeric monoclonal IgG1 antibody against TNF-α [34].
It neutralizes TNF-α biological activity and inhibits bone distraction [35]. However,
one side-effect of infliximab includes immunodeficiency, therefore it needs to be
use cautiously.
22.4 The Inhibitory Effect of the Anti-c-Fms Antibody
in Pathological Osteoclast Formation and Bone
Resorption
In this review, we describe and discuss the effect of the anti-c-Fms antibody on the
pathology of osteoclastogenesis and bone resorption. M-CSF is produced by mes-
enchymal cells and its regulated secretion has physiological and pathological
consequences for osteoclasts. M-CSF promotes the survival and longevity of
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osteoclast precursors and organizes osteoclast cytoskeletons [15]. The absence of
estrogen in post-menopausal osteoporosis is because of enhanced bone resorption
caused by increased production of M-CSF by marrow stromal cells [24]. The level
of M-CSF is increased in the serum of patients with RA who have severe ankylos-
ing spondylitis [36] and in the synovial fluid around loose joint prostheses
[28]. These observations suggest that stromal cell-produced M-CSF may be an
important mediator of inflammation-induced osteoclastogenesis. Indeed, it has been
reported that TNF-α induces M-CSF gene expression in stromal cells and increases
the number of osteoclast precursors in vivo [37]. Stromal cell-produced M-CSF
may be an important mediator of TNF-stimulated osteoclastogenesis. In fact,
TNF-α has been shown to induce M-CSF gene expression in vivo and only in the
presence of stromal cell-residing TNFRs. The capacity of TNF-α to increase
osteoclast precursor numbers in vivo, corresponds with the pro-proliferative and
pro-survival properties of abundant levels of M-CSF. The fact that TNF-α enhances
osteoclast precursor numbers in the presence of only constitutive levels of M-CSF,
suggests that, like its interaction with RANKL, this inflammatory cytokine
synergizes with M-CSF to enhance osteoclast precursor numbers. In fact, mice
treated with carrier or anti-c-Fms mAb developed equivalent periarticular inflam-
mation, while those receiving the antibody were completely free of pathological
osteoclastogenesis and bone resorption. This observation reflects, to a substantial
degree, the arrest of TNF signaling, as similar results were obtained in
TNF-α-injected mice also receiving the anti-c-Fms antibody.
Mechanical force loading exerts important effects on the skeleton by controlling
bone mass and strength. Orthodontic tooth movement is a good model for exploring
the mechanism of mechanical loading-induced bone remodeling. In a mouse model
of orthodontic tooth movement, TNF-α was expressed and osteoclasts appeared on
the compressed side of the periodontal ligament. In TNF-receptor-deficient mice,
there was less tooth movement and osteoclast numbers were lower than in wild-type
mice. These results suggest that osteoclast formation and bone resorption are
caused by mechanical loading-induced TNF-α secretion and that TNF-α is
concerned with orthodontic tooth movement [38]. However, the relationship
between orthodontic movement and TNF-α is not fully understood as yet. Blocking
M-CSF with an anti-c-Fms antibody was shown to inhibit osteoclast formation and
tooth movement [39]. These results suggest that control of M-CSF could regulate
osteoclast formation and subsequent orthodontic tooth movement. Root resorption
often occurs following orthodontic treatment and is a serious problem for the
orthodontist and patient. During one study, the anti-c-Fms antibody was locally
injected adjacent to the first molar every other day during the experimental period.
The anti-c-Fms antibody was found to inhibit odontoclastogenesis and root resorp-
tion during orthodontic tooth movement [39].
M-CSF and/or its receptor is therefore a potential therapeutic target in mechan-
ical stress-induced odontoclastogenesis, and injection of the anti-c-Fms antibody
might be useful for inhibition of mechanical stress-induced root resorption during
orthodontic tooth movement.
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Bacterial infection and lipopolysaccharide (LPS) are reported to induce osteo-
clast formation and inflammatory bone loss, as seen in periodontal diseases [40,
41]. LPS is major component of bacteria and is reported to be an inducer of
inflammation and pathological bone resorption. We therefore, aimed to examine
the effect of LPS on osteoclastogenesis and the anti-c-Fms antibody. We assumed
that the M-CSF receptor c-Fms antibody would inhibit LPS-induced osteoclast
formation. In our study, we showed that LPS induced M-CSF expression in vivo.
The anti-c-Fms antibody has been previously reported to inhibit RANKL-induced
osteoclastogenesis in vitro and completely block pathological osteoclastogenesis
and bone resorption, induced by inflammatory arthritis and direct injection of
TNF-α [42]. In the present study, we administered LPS with and without the anti-
c-Fms antibody into mouse supracalvariae to analyze the effect of the anti-c-Fms
antibody on LPS-induced osteoclastogenesis in vivo. In the LPS-administered
group, increased numbers of osteoclasts were observed. In comparison, the number
of osteoclasts was significantly reduced in the group administered with both LPS
and the anti-c-Fms antibody, which was dependent on the concentration of the anti-
c-Fms antibody. Levels of both cathepsin K and tartrate-resistant acid phosphatase
mRNAs were also significantly lower in the group administered with both LPS and
the anti-c-Fms antibody compared with the LPS-administered group. These results
showed that anti-c-Fms antibody inhibited LPS-induced osteoclast formation
[43]. To examine whether the anti-c-Fms antibody inhibited LPS-induced
osteolysis, we used three-dimensional reconstruction images of calvariae obtained
by microfocal computed tomography (μ-CT). Many radiolucent spots on calvariae
were observed in the μ-CT images in the LPS-administered group but not in the
group administered both LPS and the anti-c-Fms antibody. Furthermore, the level
of TRACP-5b, a bone resorption marker, was lower in the serum of the group
administered both LPS and the anti-c-Fms antibody compared with the
LPS-administered group. The results suggest that the anti-c-Fms antibody can
inhibit LPS-induced osteolysis by inhibition of osteoclast formation [43]. Our
results showed that osteoclasts were induced in calvariae in the presence of LPS.
Several previous studies have indicated that LPS induces the expression of inflam-
matory cytokines, such as TNF-a, IL-1, and IL-6, in vitro and in vivo. Furthermore,
it has been reported that TNF-α induces M-CSF expression in stromal cells in vivo
[42, 44]. In our study, we found that LPS induced M-CSF expression in vivo. It has
been reported that M-CSF induces RANK expression by bone marrow macro-
phages in vitro [42]. We therefore investigated whether LPS-induced RANK
expression in vivo was dependent on M-CSF. We found LPS-induced RANK
gene and protein expression were inhibited by the anti-c-Fms antibody in vivo
[43]. These results suggest that RANK expression induced by LPS in vivo might be
dependent on LPS-induced M-CSF levels. Taken together, the inhibition of
LPS-induced RANK expression might be one factor behind the inhibitory effect
of the anti-c-Fms antibody on osteoclastogenesis.
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22.5 Conclusions
M-CSF has an important role within the immune system and bone remodeling,
representing one of many cytokines involved in the pathogenesis of inflammatory
osteolysis. Although M-CSF-signaling is initiated at the induction of the arthritic
process, the profundity of its effect on osteoclasts, as compared with macrophages,
enhances its therapeutic appeal. The potential of M-CSF inhibition as a means of
treating RA is underscored by the development of c-Fms-selective small molecules
[45] and the capacity of the tyrosine kinase inhibitor drug, imatinib, to target the
receptor [46]. Given the significant complications encountered with other forms of
anti-cytokine therapy, however, the therapeutic targeting of M-CSF must be
approached with caution [47]. M-CSF and/or its receptor are potential therapeutic
targets for the treatment of bacterial infection-induced osteolysis caused by LPS.
The injection of an anti-c-Fms antibody might be useful for the inhibition of
pathological bone resorption during bacterial infection.
Taken together, these data indicate that M-CSF is a key cytokine that plays a
central role in inflammatory osteolysis and might be a therapeutic target. However,
M-CSF accelerates formation of osteoclasts by increasing their precursor pool, the
majority of which fail to become bone resorptive polykaryons, but host defense
mononuclear phagocytes. Thus, the coincident immunosuppressive effect of
inhibiting macrophage proliferation and survival as a means of arresting inflamma-
tory periarticular erosion, is a potential limitation of M-CSF blockade. Further
studies are necessary to clarify this aspect.
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